抗心律失常药物与多发性神经病。多发性神经病研究协作组。
Antiarrhythmic drugs and polyneuropathy. The Collaborative Group for the Study of Polyneuropathy.
出版信息
J Neurol Neurosurg Psychiatry. 1994 Mar;57(3):340-3. doi: 10.1136/jnnp.57.3.340.
A total of 151 patients on chronic treatment with amiodarone and other antiarrhythmic drugs were subjected to standard clinical and electrophysiological investigation to assess the prevalence and specificity of polyneuropathy. Twenty two untreated patients with cardiac disorders and 246 normal subjects served as controls. Abnormal electrophysiological findings supporting the diagnosis of polyneuropathy were present in 38 subjects (25%) given antiarrhythmic drugs, with even distribution among drugs, and four untreated patients (18%). Concurrent clinical abnormalities were present in five treated patients (one each with amiodarone, propafenone, and flecainide, and two with multiple drugs). Therefore, electrophysiological abnormalities are a common, although non-specific, feature in patients taking antiarrhythmic drugs. Amiodarone users do not seem at higher risk of polyneuropathy than subjects treated with other drugs or even untreated patients with cardiac disorders.
共有151例接受胺碘酮和其他抗心律失常药物长期治疗的患者接受了标准的临床和电生理检查，以评估多发性神经病的患病率和特异性。22例未接受治疗的心脏病患者和246名正常受试者作为对照。接受抗心律失常药物治疗的38名受试者（25%）出现了支持多发性神经病诊断的异常电生理结果，且在各类药物中分布均匀，4名未接受治疗的患者（18%）也出现了这种情况。5名接受治疗的患者同时存在临床异常（1名使用胺碘酮，1名使用普罗帕酮，1名使用氟卡尼，2名使用多种药物）。因此，电生理异常是服用抗心律失常药物患者的一个常见特征，尽管不具有特异性。使用胺碘酮的患者患多发性神经病的风险似乎并不高于使用其他药物治疗的患者，甚至不比未接受治疗的心脏病患者高。
Zotero 插件